ASCO Poster has gone live:

New Post Public Reply Private Reply Replies (1) Message Board
TheProgressive
Initial Takeaways from the poster:

The Phase 1 trial began November 7, 2012.
•A total of 10 patients have been enrolled to date.
•Cohorts 0, 1 and 2 have been completed without DLT.
•The MTD has not yet been reached; the trial is ongoing

Very wide range of patients with solid tumors being tested (liver, lungs, overian, pancreatic, etc etc), one person has completed 7 cycles!

No DLT confirmed so far through first 3 cohorts, let's not lose sight of this very important and positive confirmation!!!

New PR to go along with ASCO Presentation:

Beverly, MA — 06/03/13 — Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces that it has published its poster on Kevetrin, the Company’s p53 modulating drug, being presented at 8:00 AM ET today at the 2013 American Society of Clinical Oncology (“ASCO”) Annual Meeting being held in Chicago, Illinois from May 31 through June 4, 2013.

The poster summarizes information from the ongoing Phase I trial being conducted at Harvard Cancer Centers, including Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Massachusetts General Hospital. Research is characterizing the pharmacokinetic profile of Kevetrin, along with evaluating preliminary evidence of anti-tumor activity and potential biomarkers of tumor response to Kevetrin by activation of p21.

The presentation is available for viewing at: http://cellceutix.com/events/

Cellceutix wishes to commend the efforts of Dr. Geoffrey Shapiro, Dr. Jeff Supko, Dr. Daniel Cho and their teams in the clinical trial and poster presentation. The Company considers itself fortunate to be working with such world-renown leaders in oncology trials and research.

“The trial, which is currently in the fourth cohort, is progressing with data to date on par with our laboratory studies,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “Through three completed cohorts, we have seen no signs of dose limiting toxicity. Dana-Farber’s extensive tumor mapping technologies will help us pinpoint which patients will benefit the most from Kevetrin as we move towards defining the Maximum Tolerated Dose. We are very pleased with the results so far and believe that as dose escalation continues, the potential therapeutic benefits will rise significantly.

Dr. Menon continued, “Some very exciting times are approaching as we expect to reach Maximum Tolerated Dose between the sixth and ninth cohorts. We also look forward to data on the p21 biomarker, which was not available for the ASCO meeting as the laboratory moves the samples into queue, in the coming weeks. As can clearly be seen in the poster, at this time ten patients have been treated with Kevetrin at low doses. Five patients have received more than one cycle of Kevetrin, including one patient who has already completed seven dosing cycles. This lends to our enthusiasm about the potential of Kevetrin and our sanguine outlook for the second half of the year.”



So, no P21 data available yet which many were hoping for, but this is very good news, about as good as we can hope for, short of announcing P21 data is available :

“The trial, which is currently in the fourth cohort, is progressing with data to date on par with our laboratory studies,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix.

We all know how the lab studies went, and if human results so far are on par with lab results.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 45

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 53

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 24

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Surgery Partners Deal Faces Fresh Price Scrutiny Ahead

Updated Category News Views 35

A $23.50 cash offer can look wonderfully tidy until somebody asks how the number was built. That is where Surgery Partners shareholders find themselves after Halper Sadeh LLC said it is investigating the proposed sale of Surgery Partners, Inc. to HealthSpan Partners. The firm is examining whether the company’s board obtained a fair price, ran a conflict-free process,...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 52

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading

Top 5 Most Recently Viewed Articles

Renesas Electronics Reveals Optimistic Financial Expectations

Updated Category News Views 68

Renesas Electronics Unveils Future Financial Outlook Renesas Electronics Corporation (TSE: 6723), a leading name in the semiconductor industry, has recently shared its consolidated financial forecasts for the complete fiscal year. This announcement highlights the Group's optimistic projections for the year ending December 31, 2024, despite the inherent volatility seen in...

Continue Reading
Atos Achieves European Leadership in Mainframe Solutions Ranking

Updated Category News Views 213

Atos Secures Top Position in ISG’s Mainframes Evaluation Atos has proudly announced its recognition as a leader in ISG’s Provider Lens™ Mainframes – Services and Solutions for the fourth consecutive year. This accolade highlights Atos' extensive experience, innovative strategies, and commitment to excellence in service delivery. Leadership in Multiple Quadrants In...

Continue Reading
Custom Upholstered Furniture: Comfort Built to Last

Updated Category News Views 150

Rethinking Furniture Comfort: Not Just a Luxury Diving into the world of custom upholstered furniture with insights from Randy Marohn is like finding a cheat sheet for comfort. Seriously, it ain't just about plush cushions or slick fabrics—it's a bonafide science. Marohn, from Sans Furniture Inc. in good ol’ Hamburg, NY, unfolds a tale of intentional design and...

Continue Reading
Cyble Achieves Users' Love Badge With Outstanding Category Wins

Updated Category News Views 84

Cyble Earns G2 'Users Love Us' Badge for Winter 2026 Cyble, a leader in the field of AI-driven cybersecurity and threat intelligence, has recently achieved significant recognition in the G2 Winter 2026 Reports. This includes acquiring the esteemed 'Users Love Us' badge, along with 18 category victories within the domains of threat intelligence, digital risk protection,...

Continue Reading
SunPower Strengthens Sales Force for Future Expansion

Updated Category News Views 210

SunPower Expands Its Sales Force to Drive Future Growth Recently, SunPower Inc. (NASDAQ: SPWR) has made significant strides in expanding its sales force after successfully integrating the sales team from Sunder Energy. The merger promises to boost SunPower's operational effectiveness while setting the stage for unprecedented revenue potential. The company is poised to...

Continue Reading